WASHINGTON (AP) - Federal regulators are investigating whether a group of
best-selling arthritis drugs made by Abbott Laboratories, Schering-Plough Corp.
and other companies heighten the risk of cancer in youngsters.
The Food and Drug Administration said Wednesday it has received 30 reports
of children and young adults developing cancer while taking the drugs over the
last 10 years. Roughly half the cases were lymphomas, a type of immune-system
cancer. Others reported were leukemia, melanoma and cancers of various organs.
The drugs under review include Abbott Labs' Humira, Schering-Plough's
Remicade, and Enbrel, which is marketed by Amgen Inc. and Wyeth. They are
prescribed to children with arthritis to block a chemical that causes
inflammation. The drugs also are used to treat children with the intestinal
disorder Crohn's disease.
The products, known as tumor necrosis factor blockers, are key revenue
drivers for the companies. Abbott's Humira was the company's best-selling
product last year with over $3 billion in sales. Remicade also topped
Schering-Plough's portfolio with sales of $1.65 billion.
The safety of Humira was reviewed in February when the FDA first cleared it
for use in juvenile arthritis, Abbott said in a statement. The company has not
recorded any instances of lymphoma in children.
Representatives from the other companies did not immediately return calls
for comment Wednesday morning.
The FDA said the drugs' labeling already warns of a potential association
with cancer, but the agency's investigation will focus on risks to younger
patients.
The statement posted to the FDA's Web site said it will take long-term
studies to definitively assess the drugs' safety risks since cancers take years
to develop.
Belgian drug maker UBC is conducting a long-term study of risks, including
cancer, with its drug Cimizia, which is part of the medication class. But the
FDA said that study won't be complete until 2019.
The agency has asked drug makers to provide all information about children
who developed cancer while taking the medications. Regulators will report the
findings of their review by November.
Doctors should consider the risks of cancer when considering prescribing the
drugs for youngsters, the FDA said.
Shares of Abbott Laboratories fell 2 cents to $55.71 in midday trading,
while Schering-Plough rose 14 cents to $20.64. Amgen shares rose 12 cents to
$44.27, while Wyeth fell 13 cents to $44.09.
Copyright 2008 Associated Press. All rights reserved. This material may not be
published, broadcast, rewritten, or redistributed.
|